31 results about "Inhibition constant" patented technology

The invention relates to novel application of berberine and derivatives thereof in preparation of medicines, in particular to application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase IDO inhibitor, belonging to the medicine field. According to IDO inhibition activity detection, reversible inhibition judgment, inhibitor type judgment, Ki value determination and median effective inhibition concentration IC50 determination, the results show that berberine is reversible inhibitor and inhibition constant Ki is 8muM; and jatrorrhizine hydrochloride and palmatine hydrochloride are irreversible inhibitors, and the median effective inhibition concentrations IC50 thereof are respectively 123muM and 126muM. When the berberine and the derivatives thereof disclosed in the invention are used as IDO inhibitors, the application prospect is wide and the IDO inhibitors can be used for treating serious diseases such as cancers, AIDS, Alzheimer diseases, tristimania, cataract and the like with pathological feature of IDO-mediated tryptophan metabolism.

Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

The invention belongs to the medicinal field, and concretely relates to a use of a 8-nitrotryptanthrin compound as an IDO inhibitor. The 8-nitrotryptanthrin compound is a reversible IDO inhibitor, has an inhibition constant Ki of 0.054muM, has in-vitro and cell-based median effective inhibition concentrations IC50 of 0.103muM and 1.80*10<-5>muM respectively, and has an inhibition effectiveness obviously better than a present inhibitor 1-methyltryptophan (Ki of 34muM and IC50 of 340muM). 8-nitrotryptanthrin disclosed in the invention can effectively lower the abnormally-increasing IDO activity in a tumor animal model as the IDO inhibitor, and also has tumor treatment effects comprising tumor growth delaying, tumor volume reduction and in-vitro tumor cell killing. 8-nitrotryptanthrin disclosed in the invention has a wide application prospect, and can be used for treating serious diseases having the IDO mediated tryptophan metabolism approach pathology characteristics, such as cancers, the Alzheimer disease, tristimania, cataract and the like as the IDO inhibitor.

Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinatiorial polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

The invention discloses application of a compound for efficient inhibition of chitinase OfChi-h and hexosaminidase OfHex1 activity, and relates to application of a compound phlegmacin B1 and its derivatives in inhibiting chitinase OfChi-h and hexosaminidase OfHex1 activity. The used final concentration is not less than 13ppm, under the concentration, the measured inhibition rates are 90.4% and 71.4% respectively, and inhibition constants Ki are 5.5 microM and 26 microM respectively. The invention proves that the compound phlegmacin B1 has good application prospect in the prevention and control of agricultural pests, especially in prevention and control of lepidoptera insects.

The invention which belongs to the field of the design and the synthesis of cathepsin (Cat for short) inhibitors concretely relates to novel and efficient hydrazine nitrile inhibitors with different P<3> structures directed to four Cats (K, B, L and S). The main structure of the hydrazine nitrile inhibitors in the invention is represented by a formula in the specification; and in the formula, R1 is isobutyl, and R2 is alkyl, aryl, or cycloalkyl. The peptidomimetic hydrazine nitrile inhibitors designed and synthesized in the invention have the advantages of relatively simple structure, and easy synthesis; and the design and the synthesis of the maternal structure provide great conveniences for the synthesis of subsequent end products. Synthesized compounds, which can effectively inhibit actives of the Cat K, the Cat B, the Cat S and the Cat L, have an inhibition constant to the Cat K and the Cat L being in a picomole concentration (10<-12>M) level; and the synthesized compounds, which have weak inhibition effects on the Cat B and the Cat S have an inhibition constant being in a nanomole concentration (10<-9>M) level.

The invention relates to D-3-phosphoglycerate-dehydrogenase and a coding gene thereof. The amino acid sequence of the D-3-phosphoglycerate-dehydrogenase is shown as a sequence 1; the inhibition constant Ki of L-serine of the D-3-phosphoglycerate-dehydrogenase is greater than 250mM; and the sequence of the coding gene is shown as a sequence 2. The difference between the amino acid sequence of the D-3-phosphoglycerate-dehydrogenase (PGDH) provided by the invention and the amino acid sequence (sequence 3) of the escherichia coli wild type PGDH lies in that amino acid at 344th site is not histidine but lactamine and amino acid at 346th site is not asparagines but lactamine and the PGDH generated by mutation is not inhibited by the L-serine. In addition, the enzyme activity of a PGDH variant disclosed by the invention has no change compared with the wild type PGDH variant.

The present invention is anti-folate antimalarials with dual-binding modes of the general formula (I) [refer to structure in the abstract] wherein R₁ and R₂ which may be the same or different are independently selected from methyl or ethyl or alkyl-phenyl, R₃ is independently hydrogen, halide, lower alkyl substituted with ester, carboxylic, amide, and ether. Linker is X(CH₂)nY wherein X and Y which may be the same or different are independently selected from oxygen, carbon, nitrogen, substituted phenyl where n is an integer from 1 to 2-6, or pharmaceutically acceptable salts therefore. The anti-folate antimalarials with dual-binding modes act as novel inhibitors with good inhibition constants against wild-type, double (C59R+SIOSN), triple (N51+C59R+SIOSN, C59R+S 1 OSN+I164L), and quadruple (N51+C59R+S108N+I164L) mutant enzymes. The compounds are also effective against wild type (Tm4/S.2) and mutants (K1CB1, W2, Cs1-2 and V1/S) malaria parasites.

The invention discloses an arginine decarboxylase mutant and an application of the arginine decarboxylase mutant in production of agmatine, which belong to the technical field of biology. The invention provides arginine decarboxylase mutants I534D and D535W which are less influenced by product inhibition. The arginine decarboxylase mutant I534D is obtained by mutating isoleucine at the 534th siteof wild-type arginine decarboxylase of which the amino acid sequence is shown as SEQ ID NO.1 into aspartic acid. The half inhibition constant of the arginine decarboxylase can reach 0.66 mol/L and isincreased by 5.5 times compared with that of wild arginine decarboxylase; the arginine decarboxylase mutant D535W is obtained by mutating aspartic acid at the 535th site of wild type arginine decarboxylase with an amino acid sequence shown as SEQ ID NO.1 into tryptophan, the half inhibition constant of the arginine decarboxylase can reach 0.50 mol/L, and is improved by 4.2 times compared with thatof wild arginine decarboxylase.

The substrate and subsite specificity of the catalytically active enzyme was determined by measuring the initial hydrolysis rate of the substrate using MALDI-TOF/MS. In addition, memapsin subsite specificity was determined by probing the inhibitor library with memapsin2 and detecting bound memapsin2 with a memapsin2 antibody and alkaline phosphatase-conjugated secondary antibody. Substrate and subsite specificity information can be used to design analogs of natural memapsin2 substrates capable of inhibiting memapsin2 function. Substrate analogs are based on peptide sequences related to the native peptide substrate of memapsin2. Substrate analogs contain at least one analog whose amide bond cannot be broken by memapsin2. A synthetic method for analogues containing isosteric substrates at key amino acid residue positions has been developed, and more than 70 substrate analogues have been synthesized, including MM1-005, MM1-012, MM1-017, MM1- 018, MM1-025, MM1-026, MM1-037, MM1-039, MM1-040, MM1-066, MM1-070 and MM1-071 correspond to recombinant pro-memapsin2 with inhibition constants in the range of 1.4-61.4×109M . These inhibitors are useful in the diagnosis, treatment and/or prevention of Alzheimer's disease.

The invention relates to a virtual screening method for a micromolecular reversible inhibitor of an alkaline metalloproteinase from flavobacterium YS-80-122 and belongs to the field of marine biotechnologies. The virtual screening method comprises the following steps: determining the type of the micromolecular reversible inhibitor according to the known structural data of the alkaline metalloproteinase from the flavobacterium YS-80-122; measuring the inhibition constant of the micromolecular reversible inhibitor of the type to the alkaline metalloproteinase from the flavobacterium YS-80-122, and determining compounds composing a training set; conducting molecular docking on the compounds of the training set and the alkaline metalloproteinase from the flavobacterium YS-80-122; acquiring the theoretical binding free energy and the theoretical reversible inhibition constant of the compounds of the training set and the alkaline metalloproteinase from the flavobacterium YS-80-122; in combination with the measured data, making a screening rule and establishing a screen model; conducting virtual screening. The virtual screening method is high in screening speed, can quickly reduce the quantity of candidate molecules, and reduce waste of time and test materials.

The invention relates to an application of a CTBS (Di-N-acetylchitobiase) protein serving as a target spot of a sperm-egg binding acceptor to screening of a sperm-egg binding inhibitor. According to the application, CTBS is a special sperm-egg binding acceptor on rodent sperm; the CTBS protein only has the specific expression on the sperms of rodents and the protein is not expressed on sperms of human beings; a CTBS antibody can inhibit the sperm-egg binding of mice. The screened sperm-egg binding acceptor is dequalinium chloride and the semi-inhibition constant is less than 100nM. The dequalinium chloride serves as fertility regulation medicine of the mice and the sperm-egg binding of the rodents can be effectively controlled, thus controlling the population quantity of the mice; the aim of controlling mouse damages without pesticides is realized; the damages are not caused when natural enemies of the mice eat the medicine.

The invention relates to a king cobra viper venom inhibitor, and relative derivative. Compared with other natural low-molecular-weight prolease inhibitor, the inventive inhibitor has simple structure, high gene expression yield, and special activity. The preparation method of the king cobra viper venom inhibitor can be prepared by separating and purifying crude venom or prepared by gene engineering. The invention further provides the application of the king cobra viper venom inhibitor and relative derivative, which has double inhibition activity of parenzyme and chymotrypsin, in same magnitude order as the inhibition constant on two proleases, and the inhibition activity with sodium channel.

The invention discloses a method for screening a helicobacter pylori urease inhibitor by using an HPUb/nPt/NPG/GCE biosensor. The method comprises the following steps of: (1) preparing and representing a HPUb/nPt/NPG/GCE biosensor; (2) detecting a response current generated by urea with the gradient concentration of 0-100mM by using the HPUb/nPt/NPG/GCE biosensor, and calculating according to a Mie's equation to obtain K<a, urea> and V<max, urea> of the urea detected by the biosensor; and (3) detecting different urease inhibitors, and screening and analyzing inhibition types and inhibition constants of the inhibitors. The HPUb/nPt/NPG/GCE biosensor developed in the method is simple in preparation process, high in detection stability and easy to store. Meanwhile, compared with other detection methods, the screening method provided by the invention does not need a complex sample pretreatment process, is simple to operate and rapid in detection, effectively shortens the potential urease inhibitor screening time, and has a wide application prospect.

The invention belongs to the technical field of cathepsin K inhibitors, and particularly relates to novel nitrile cathepsin K inhibitors using cathepsin K as target protein and trifluoroethylamino groups as P2-P3 linkers and having different P3 position structures. The P2-P3 linkers are trifluoroethylamino groups, P3 positions are aryl groups comprising a bromophenyl group, a p-biphenyl group, a p-terphenyl group and a p-methyl biphenyl group. The nitrile inhibitors have the advantages that the structures are simple relatively, the synthesis is convenient, and the yield is high; inhibition constants (Ki) of the compounds (the inhibitors) to cathepsin K are in the picomole level, so that the effective inhibiting ability to the cathepsin K is reflected; when the P3 position is the P-terphenyl group, the inhibiting ability and the selectivity of the inhibitor to the Cat K (the cathepsin K) are better than those of corresponding amide inhibitors. In vitro cytotoxicity tests show that the inhibitors are free of cytotoxicity, and have the possibility of being applied to clinical trials and being used as potential anti-osteoporosis drug.